- Home
- DNLI vs TARS Comparison
DNLI vs TARS Comparison
Compare DNLI & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DNLI
- TARS
- Stock Information
- Founded
- DNLI 2013
- TARS 2016
- Country
- DNLI United States
- TARS United States
- Employees
- DNLI N/A
- TARS N/A
- Industry
- DNLI Biotechnology: Biological Products (No Diagnostic Substances)
- TARS Medicinal Chemicals and Botanical Products
- Sector
- DNLI Health Care
- TARS Health Care
- Exchange
- DNLI Nasdaq
- TARS Nasdaq
- Market Cap
- DNLI 2.1B
- TARS 1.7B
- IPO Year
- DNLI 2017
- TARS 2020
- Fundamental
- Price
- DNLI $13.92
- TARS $40.20
- Analyst Decision
- DNLI Strong Buy
- TARS Strong Buy
- Analyst Count
- DNLI 15
- TARS 7
- Target Price
- DNLI $33.85
- TARS $67.14
- AVG Volume (30 Days)
- DNLI 1.7M
- TARS 593.2K
- Earning Date
- DNLI 07-31-2025
- TARS 08-07-2025
- Dividend Yield
- DNLI N/A
- TARS N/A
- EPS Growth
- DNLI N/A
- TARS N/A
- EPS
- DNLI N/A
- TARS N/A
- Revenue
- DNLI N/A
- TARS $233,674,000.00
- Revenue This Year
- DNLI N/A
- TARS $122.94
- Revenue Next Year
- DNLI $335.74
- TARS $44.14
- P/E Ratio
- DNLI N/A
- TARS N/A
- Revenue Growth
- DNLI N/A
- TARS 449.03
- 52 Week Low
- DNLI $10.57
- TARS $20.08
- 52 Week High
- DNLI $33.33
- TARS $57.28
- Technical
- Relative Strength Index (RSI)
- DNLI 48.38
- TARS 41.69
- Support Level
- DNLI $13.83
- TARS $39.50
- Resistance Level
- DNLI $14.66
- TARS $41.50
- Average True Range (ATR)
- DNLI 0.63
- TARS 1.48
- MACD
- DNLI -0.03
- TARS 0.11
- Stochastic Oscillator
- DNLI 31.58
- TARS 44.35
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.
About TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.